Prevention of postpartum depression: a pilot randomized clinical trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 15229064.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors attempted to reduce the rate of postpartum depression in high-risk women and to increase the time to recurrence. Nondepressed pregnant women with at least one past episode of postpartum major depression were recruited into a randomized clinical trial. Mothers were assigned randomly to a 17-week trial of sertraline or placebo immediately after birth and assessed for 20 sequential weeks with the Hamilton Rating Scale for Depression. Of 14 subjects who took sertraline, one (7%) suffered a recurrence. Of eight subjects who were assigned to placebo, four (50%) suffered recurrences. This difference was significant. The time to recurrence was significantly longer in the sertraline-treated women than in the placebo-treated women. Sertraline conferred preventive efficacy for postpartum-onset major depression beyond that of placebo.
Medical subject headings
- Depression, Postpartum
- Secondary Prevention
- Selective Serotonin Reuptake Inhibitors
- Sertraline